tetano
Editor, Senior Moderator
Vaccine
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.08.073 | How to Cite or Link Using DOI
Permissions & Reprints
Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults
Alan Leeba, Corresponding Author Contact Information, E-mail The Corresponding Author, Dale Carcioneb, Peter C. Richmondc, d, Peter Jacobyd and Paul V. Efflerb
a Illawarra Medical Centre, Ballajura, Western Australia, Australia
b Communicable Disease Control Directorate, Department of Health, Perth, Western Australia, Australia
c School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia
d Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, West Perth, Western Australia, Australia
Received 10 May 2011;
revised 2 August 2011;
accepted 15 August 2011.
Available online 22 August 2011.
Abstract
Objective
To assess the reactogenicity of two 2010 trivalent inactivated influenza vaccine (TIV) formulations among adults, including the formulation associated with febrile convulsions among children in Australia.
Design, setting and participants
We retrospectively interviewed persons aged ≥18 years who received TIV between 11 March and 24 April 2010 at a large general practice in Perth. All 160 persons who received Influvac? (Solvay) and a random sample of 190 of 451 persons who received Fluvax? (CSL Biotherapies) were included in the assessment; 127 (79%) recipients of Influvac? and 156 (82%) of the Fluvax? recipients completed the interview.
Main outcome measures
Patient demographics, the presence of underlying medical conditions, prior influenza vaccination history, self-reported onset of local and/or systemic symptoms within 72 h following receipt of 2010 TIV, and use of anti-fever/pain medication following TIV vaccination were examined.
Results
The mean age of the vaccinees was 54 years for both the Fluvax? and Influvac? brand cohorts and there was no significant difference between the cohorts with regard to gender or the presence of underlying medical conditions. In bivariate analyses, reported swelling (18% vs 7%, p = 0.009), muscle pain (12% vs 3%, p = 0.014) and use of anti-fever/pain medication after TIV vaccination (12% vs 2%, p = 0.008) were each significantly more common for patients who received Fluvax? compared to those who received Influvac?. In multivariate analyses simultaneously controlling for age, gender, receipt of seasonal influenza vaccine prior to 2010 and receipt of 2009 H1N1 pandemic vaccine, vaccination with Fluvax? TIV was a significant independent predictor of muscle pain and/or swelling (OR = 3.3, 95% CI 1.5?7.4 p = 0.004). No significant differences in the proportion of patients reporting systemic reactions were observed.
Conclusions
In this setting, 2010 Fluvax? was associated with a greater likelihood of local reactions among adults, compared to 2010 Influvac? TIV.
Highlights
► In 2010 CSL influenza vaccine was linked to increased febrile adverse events in children. ► We compared the reactogenicity of the 2010 CSL influenza vaccine to another brand among adults. ► Swelling and muscle pain were significantly more common among adults who received CSL vaccine. ► Increased reactions in both children and adults suggests the potential for a common causal pathway.
http://www.sciencedirect.com/science/article/pii/S0264410X11013326
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.08.073 | How to Cite or Link Using DOI
Permissions & Reprints
Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults
Alan Leeba, Corresponding Author Contact Information, E-mail The Corresponding Author, Dale Carcioneb, Peter C. Richmondc, d, Peter Jacobyd and Paul V. Efflerb
a Illawarra Medical Centre, Ballajura, Western Australia, Australia
b Communicable Disease Control Directorate, Department of Health, Perth, Western Australia, Australia
c School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia
d Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, West Perth, Western Australia, Australia
Received 10 May 2011;
revised 2 August 2011;
accepted 15 August 2011.
Available online 22 August 2011.
Abstract
Objective
To assess the reactogenicity of two 2010 trivalent inactivated influenza vaccine (TIV) formulations among adults, including the formulation associated with febrile convulsions among children in Australia.
Design, setting and participants
We retrospectively interviewed persons aged ≥18 years who received TIV between 11 March and 24 April 2010 at a large general practice in Perth. All 160 persons who received Influvac? (Solvay) and a random sample of 190 of 451 persons who received Fluvax? (CSL Biotherapies) were included in the assessment; 127 (79%) recipients of Influvac? and 156 (82%) of the Fluvax? recipients completed the interview.
Main outcome measures
Patient demographics, the presence of underlying medical conditions, prior influenza vaccination history, self-reported onset of local and/or systemic symptoms within 72 h following receipt of 2010 TIV, and use of anti-fever/pain medication following TIV vaccination were examined.
Results
The mean age of the vaccinees was 54 years for both the Fluvax? and Influvac? brand cohorts and there was no significant difference between the cohorts with regard to gender or the presence of underlying medical conditions. In bivariate analyses, reported swelling (18% vs 7%, p = 0.009), muscle pain (12% vs 3%, p = 0.014) and use of anti-fever/pain medication after TIV vaccination (12% vs 2%, p = 0.008) were each significantly more common for patients who received Fluvax? compared to those who received Influvac?. In multivariate analyses simultaneously controlling for age, gender, receipt of seasonal influenza vaccine prior to 2010 and receipt of 2009 H1N1 pandemic vaccine, vaccination with Fluvax? TIV was a significant independent predictor of muscle pain and/or swelling (OR = 3.3, 95% CI 1.5?7.4 p = 0.004). No significant differences in the proportion of patients reporting systemic reactions were observed.
Conclusions
In this setting, 2010 Fluvax? was associated with a greater likelihood of local reactions among adults, compared to 2010 Influvac? TIV.
Highlights
► In 2010 CSL influenza vaccine was linked to increased febrile adverse events in children. ► We compared the reactogenicity of the 2010 CSL influenza vaccine to another brand among adults. ► Swelling and muscle pain were significantly more common among adults who received CSL vaccine. ► Increased reactions in both children and adults suggests the potential for a common causal pathway.
http://www.sciencedirect.com/science/article/pii/S0264410X11013326